MCID: PNV001
MIFTS: 52

Panuveitis

Categories: Rare diseases, Eye diseases

Aliases & Classifications for Panuveitis

MalaCards integrated aliases for Panuveitis:

Name: Panuveitis 12 53 55 44 15 73
Diffuse Uveitis 12 53
Inflammation of the Whole Uveal Tract 53
Total Uveitis 53

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

Disease Ontology 12 DOID:12030
ICD10 33 H44.11
ICD9CM 35 360.12
MeSH 44 D015864
NCIt 50 C84989
SNOMED-CT 68 75614007
UMLS 73 C0030343

Summaries for Panuveitis

NIH Rare Diseases : 53 Panuveitis is inflammation of all layers of the uvea of the eye, which includes the iris, ciliary body, and choroid. These make up the middle layer of the eye. The condition can also affect the lens, retina, optic nerve, and vitreous, causing reduced vision or blindness. Signs and symptoms may include eye redness and pain; blurring; light sensitivity; decreased vision; and seeing floaters. It can last for a short time or can occur chronically. Severe cases may recur many times. In many cases the specific cause is unknown, but in some cases it occurs in association with other eye conditions, or with another condition or infection that also affects other body parts. Early treatment is needed and may include eye drops to reduce inflammation and pain; and/or oral medications or injections in severe cases.

MalaCards based summary : Panuveitis, also known as diffuse uveitis, is related to multifocal choroiditis and choroiditis. An important gene associated with Panuveitis is UACA (Uveal Autoantigen With Coiled-Coil Domains And Ankyrin Repeats), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Influenza A. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Panuveitis

Diseases in the Panuveitis family:

Infectious Panuveitis

Diseases related to Panuveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 274)
# Related Disease Score Top Affiliating Genes
1 multifocal choroiditis 31.7 IL10 TNF
2 choroiditis 31.6 IL10 TNF
3 punctate inner choroidopathy 31.2 IL10 TNF
4 vogt-koyanagi-harada disease 31.0 HLA-B HLA-DQB1 HLA-DRB1 IL10 IL17A
5 posterior uveitis 30.6 RBP3 SAG TNF
6 neurosyphilis 30.5 IL10 IL17A
7 intermediate uveitis 30.4 HLA-B IL10 TNF
8 pulmonary tuberculosis 30.3 HLA-DRB1 IL10 TNF
9 whipple disease 29.9 HLA-DQB1 HLA-DRB1 MRAP
10 dermatitis, atopic 29.8 IL10 IL17A TNF
11 crohn's disease 29.6 IL10 TNF TNFRSF1B
12 leishmaniasis 29.6 HLA-DQB1 HLA-DRB1 IL10 TNF
13 leptospirosis 29.5 CD40LG IL10 TNF
14 asymptomatic neurosyphilis 29.4 CD40LG IL17A
15 vasculitis 29.3 CD40LG TNF TNFRSF1B
16 brucellosis 29.3 CD40LG IL10 TNF
17 multiple sclerosis 29.2 HLA-DQB1 HLA-DRB1 IL10 IL17A TNF
18 lyme disease 29.2 CD40LG IL17A TNF
19 meningitis 29.2 CD40LG IL10 TNF
20 histoplasmosis 29.1 HLA-B HLA-DRB1
21 pneumonia 29.1 CD40LG IL10 TNF
22 psoriasis 29.1 IL10 IL17A TNF TNFRSF1B
23 uveitis 28.6 HLA-B IL10 IL17A RBP3 SAG TNF
24 chorioretinitis 28.6 CD40LG MRAP RBP3 SAG
25 graft-versus-host disease 28.5 HLA-B HLA-DQB1 HLA-DRB1 IL10 TNF
26 arthritis 28.5 HLA-DQB1 HLA-DRB1 IL10 IL17A TNF TNFRSF1B
27 acquired immunodeficiency syndrome 28.4 CD40LG HLA-B IL10 TNF
28 rubella 27.1 CD40LG HLA-B HLA-DQB1 HLA-DRB1 IL10 TNF
29 idiopathic panuveitis 12.0
30 infectious panuveitis 11.9
31 tropical endomyocardial fibrosis 10.9 IL10 TNF
32 tungiasis 10.8 IL10 TNF
33 endomyocardial fibrosis 10.8 IL10 TNF
34 transient hypogammaglobulinemia 10.8 IL10 TNF
35 juvenile myasthenia gravis 10.8 HLA-DRB1 IL10
36 limbic encephalitis with lgi1 antibodies 10.8 HLA-DQB1 HLA-DRB1
37 trichosporonosis 10.8 IL17A TNF
38 trichuriasis 10.7 IL10 TNF
39 mucocutaneous leishmaniasis 10.7 IL10 TNF
40 metal allergy 10.7 HLA-DQB1 HLA-DRB1
41 posterior scleritis 10.7 MRAP TNF
42 focal epithelial hyperplasia 10.7 HLA-DQB1 HLA-DRB1
43 hypersomnia 10.7 HLA-DQB1 HLA-DRB1
44 lichen planopilaris 10.7 HLA-DQB1 HLA-DRB1
45 type ii mixed cryoglobulinemia 10.7 HLA-DQB1 HLA-DRB1
46 clonorchiasis 10.7 IL10 TNF
47 recurrent respiratory papillomatosis 10.7 HLA-DQB1 HLA-DRB1
48 anca-associated vasculitis 10.7 HLA-DRB1 TNF
49 actinic prurigo 10.6 HLA-DRB1 TNF
50 transverse myelitis 10.6 IL10 IL17A TNF

Graphical network of the top 20 diseases related to Panuveitis:



Diseases related to Panuveitis

Symptoms & Phenotypes for Panuveitis

GenomeRNAi Phenotypes related to Panuveitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 CD40LG HLA-DQB1 IL10 IL17A TNF TNFRSF1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 CD40LG HLA-DQB1 IL10 IL17A TNF TNFRSF1B

MGI Mouse Phenotypes related to Panuveitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.76 CD40LG CYP11B1 HLA-DQB1 IL10 IL17A TNF
2 renal/urinary system MP:0005367 9.43 CD40LG CYP11B1 HLA-DQB1 IL17A TNFRSF1B UACA
3 respiratory system MP:0005388 9.1 HLA-DQB1 IL10 IL17A TNF TNFRSF1B UACA

Drugs & Therapeutics for Panuveitis

Drugs for Panuveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
3
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 67-73-2 6215
4
Azathioprine Approved Phase 4,Phase 2 446-86-6 2265
5
Infliximab Approved Phase 4,Phase 3,Phase 1,Phase 2 170277-31-3
6
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
7
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
8
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
10
Ganciclovir Approved, Investigational Phase 4,Not Applicable 82410-32-0 3454
11
Chlorambucil Approved Phase 4 305-03-3 2708
12
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
13
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
14
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
15
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
16
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
17
Timolol Approved Phase 4 26839-75-8 33624 5478
18
Travoprost Approved Phase 4 157283-68-6 5282226
19
Certolizumab pegol Approved Phase 4 428863-50-7
20
Maleic acid Experimental Phase 4 110-16-7 444266
21 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Antitubercular Agents Phase 4,Phase 3
45 Cyclosporins Phase 4,Phase 3
46 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
49 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 155)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4 methylorednisolone
2 Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
3 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
4 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG Completed NCT01978015 Phase 4 travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose
5 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation Completed NCT03133767 Phase 4 Lactated Ringer Solution;Normal Saline 0.9% Infusion Solution Bag
6 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
7 Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Recruiting NCT02769702 Phase 4 Acthar
8 Study of the Effectiveness of Ozurdex for the Control of Uveitis Recruiting NCT02049476 Phase 4 Dexamethasone pellet
9 Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis Recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
10 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
11 A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU Active, not recruiting NCT03020992 Phase 4 Certolizumab Pegol
12 To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis Unknown status NCT00372294 Phase 3 pyrimethamine-sulfadiazine + prednisolone;Clindamycin+Dexamethasone
13 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis Completed NCT01148225 Phase 3 adalimumab
14 A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
15 A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
16 Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis Completed NCT00407056 Phase 3 Difluprednate Ophthalmic Emulsion
17 Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Completed NCT00406887 Phase 3 Difluprednate Ophthalmic Emulsion
18 Phase III Study in Refractory Behcet's Disease Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
19 Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
20 A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis Completed NCT00404885 Phase 3 Placebo;LX211;LX211;LX211
21 Efficacy and Safety of Adalimumab in Patients With Active Uveitis Completed NCT01138657 Phase 3 Prednisone;Placebo
22 A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT02748512 Phase 3 FAI insert
23 Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
24 Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis Completed NCT01243983 Phase 3 LX211
25 Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis Completed NCT03097315 Phase 3
26 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
27 Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants Completed NCT00407082 Phase 2, Phase 3 fluocinolone acetonide intravitreal implant;Fluocinolone acetonide 2.1mg
28 Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis Completed NCT01505088 Phase 3 40 mg/mL Dexamethasone phosphate ophthalmic solution;Prednisolone Acetate (1%) Eyedrops;100 mM sodium citrate buffer solution;Placebo Eyedrops
29 Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis Completed NCT01201798 Phase 3 Difluprednate 0.05% ophthalmic emulsion;Prednisolone acetate 1.0% ophthalmic suspension
30 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
31 Myfortic for the Treatment of Non-infectious Intermediate Uveitis Completed NCT01092533 Phase 3 Myfortic;Decortin
32 Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions Completed NCT01532570 Phase 3 TA-650
33 A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease Completed NCT01243671 Phase 3
34 Efficacy of Humira in Behcet Patients With Arthritis Completed NCT01497717 Phase 3 Adalimumab (Humira)
35 Intravitreal Bevacizumab for Inflammatory Neovascular Membranes Completed NCT00407121 Phase 3 Bevacizumab
36 Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis Completed NCT00344253 Phase 3 Interferon beta;Methotrexate
37 Interferon α2a Versus Cyclosporine for Refractory Behçet`s Disease Uveitis Recruiting NCT03209219 Phase 3 Interferon Alfa-2A;Cyclosporine Pill
38 A Phase 3 Study to Evaluate ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis. Recruiting NCT03131154 Phase 3 ADX-102 Ophthalmic Solution (0.5%);Vehicle of ADX-102 Ophthalmic Solution
39 Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Posterior Uveitis Active, not recruiting NCT02746991 Phase 3 Sham Injection;FAI Insert
40 Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert Active, not recruiting NCT01694186 Phase 3 FAI insert;Sham injection
41 Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis Active, not recruiting NCT02517619 Phase 3 Dexamethasone Phosphate Ophthalmic Solution;Prednisolone Acetate Ophthalmic (1%)
42 A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease Active, not recruiting NCT02505568 Phase 3 Infliximab
43 A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behcet's Disease Active, not recruiting NCT02307513 Phase 3 Apremilast (CC-10004);Placebo
44 Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis Not yet recruiting NCT03576898 Phase 2, Phase 3 Topical ganciclovir versus oral valganciclovir versus placebo
45 Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease Not yet recruiting NCT03371095 Phase 3 Infliximab;Cyclophosphamide
46 Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Terminated NCT01032915 Phase 3 Placebo
47 38 Week Extension Study to CAIN457C2303 Terminated NCT01093846 Phase 3 AIN457;AIN457;Placebo AIN457
48 Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
49 Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
50 Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis Terminated NCT01684345 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab

Search NIH Clinical Center for Panuveitis

Cochrane evidence based reviews: panuveitis

Genetic Tests for Panuveitis

Anatomical Context for Panuveitis

MalaCards organs/tissues related to Panuveitis:

41
Eye, Retina, Endothelial, T Cells, Testes, Skin, Neutrophil

Publications for Panuveitis

Articles related to Panuveitis:

(show top 50) (show all 221)
# Title Authors Year
1
Spectral optical coherence tomography findings in an elderly patient with syphilitic bilateral chronic panuveitis. ( 29468221 )
2018
2
Seasonal Hyperacute Panuveitis in Nepal: A Review over 40A Years of Surveillance. ( 29543556 )
2018
3
Challenging treatment of bilateral multiple infection panuveitis in HIV/AIDS patients. ( 29977825 )
2018
4
Pseudo-panuveitis masquerade syndrome associated with an orbital and systemic MALT-type B-cell lymphoma. ( 29567022 )
2018
5
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. ( 29611087 )
2018
6
Two cases of cytomegalovirus panuveitis in immunocompetent patients. ( 29780935 )
2018
7
Sarcoidosis presenting as Wallenberg syndrome and panuveitis. ( 29977748 )
2018
8
Progressive Depigmentation in a Patient with Panuveitis and Meningitis. ( 29457006 )
2018
9
Varicella-zoster virus necrotising retinitis, retinal vasculitis and panuveitis following uncomplicated chickenpox in an immunocompetent child. ( 29622711 )
2018
10
Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials. ( 28689898 )
2017
11
Morphometric features on enhanced depth imaging optical coherence tomography scans in idiopathic posterior uveitis or panuveitis. ( 28585111 )
2017
12
Acute hypotony maculopathy following the initiation of a topical aqueous suppressant in a patient with a history of panuveitis without prior filtering surgery. ( 29260088 )
2017
13
Severe panuveitis in neuro-BehAset's disease in Malaysia: a case series. ( 28223848 )
2017
14
A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. ( 29183563 )
2017
15
Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis. ( 28477440 )
2017
16
Quality-of-Life Outcomes From a Randomized Clinical Trial Comparing Antimetabolites for Intermediate, Posterior, and Panuveitis. ( 28414043 )
2017
17
Re: Jaffe etA al.: Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: 2-year results (Ophthalmology. 2016;123:1940-1948). ( 28734339 )
2017
18
Panuveitis simulating ocular BehAset's in cases of chronic myelogenous leukaemia in remission. ( 29170182 )
2017
19
Multiple myeloma masquerading as panuveitis in a middle-aged woman. ( 29308780 )
2017
20
Re: Jaffe etA al.: Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results (Ophthalmology. 2016;123:1940-1948). ( 28335961 )
2017
21
IgG4-related disease presenting as panuveitis without scleral involvement. ( 28243891 )
2017
22
Multifocal Choroiditis and Panuveitis - difficulties in diagnosis and treatment. ( 29516050 )
2017
23
Panuveitis-like reaction following encircling laser retinopexy/cerclage in a 21-year-old male. ( 29038978 )
2017
24
Toxoplasma gondii-Associated Bilateral Panuveitis and Encephalitis after Bone Marrow Transplantation. ( 29156468 )
2017
25
Ocular Autoimmune Systemic Inflammatory Infectious Study - Report 3: Posterior and Panuveitis. ( 28991501 )
2017
26
Enhanced depth imaging optical coherence tomography in patients with different phases of Behcet's panuveitis. ( 28237149 )
2017
27
Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. ( 28426849 )
2017
28
Vision-threatening bilateral panuveitis and TRAPS in a child: an uncommon association. ( 29256170 )
2017
29
Dress syndrome and bilateral panuveitis caused by strontium ranelate. ( 28662886 )
2017
30
Choroidal Vascularity Index (CVI)--A Novel Optical Coherence Tomography Parameter for Monitoring Patients with Panuveitis? ( 26751702 )
2016
31
Multiple Sclerosis and Panuveitis: A Rare Association. ( 28360778 )
2016
32
TARANTULA HAIR ASSOCIATED PANUVEITIS TREATED WITH SUSTAINED-RELEASE INTRAVITREAL DEXAMETHASONE IMPLANT. ( 27472515 )
2016
33
Canine panuveitis: a retrospective evaluation of 55 cases (2000-2015). ( 27734587 )
2016
34
Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. ( 26932535 )
2016
35
Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. ( 26712559 )
2016
36
Long-term Management of Panuveitis and Iris Heterochromia in an Ebola Survivor. ( 27594198 )
2016
37
Idiopathic Orbital Inflammation Presenting with Bilateral Panuveitis. ( 27112170 )
2016
38
A Hemophagocytic Lymphohistiocytosis Patient that Presented With Unilateral Panuveitis. ( 26731243 )
2016
39
Zika Virus Infection in Mice Causes Panuveitis with Shedding of Virus in Tears. ( 27612415 )
2016
40
Dengue Fever-Associated Maculopathy and Panuveitis in Australia. ( 28078150 )
2016
41
A Case of Severe Panuveitis Associated with Psoriasis Vulgaris Successfully Treated with Infliximab. ( 27239187 )
2016
42
GRAFT-VERSUS-HOST DISEASE PANUVEITIS AND BILATERAL SEROUS DETACHMENTS: MULTIMODAL IMAGING ANALYSIS. ( 27571426 )
2016
43
Human Immunodeficiency Virus-Infected Man With Acute Visual Impairment and Panuveitis Due to Syphilis Despite Initially Negative Rapid Plasma Reagin. ( 27893602 )
2016
44
Topical difluprednate for treatment of serous retinal detachment and panuveitis associated with Vogt-Koyanagi-Harada disease. ( 27582676 )
2016
45
Nodular Scleritis in Association with Panuveitis in BehAset's Disease. ( 28289688 )
2016
46
Differentiation of severe bilateral panuveitis following phacoemulsification: a case report. ( 27277218 )
2016
47
Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results. ( 27421623 )
2016
48
Multifocal choroiditis with panuveitis in an 8-year-old boy with long-standing idiopathic acute anterior uveitis. ( 26951535 )
2016
49
Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis. ( 26286265 )
2015
50
Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. ( 26298715 )
2015

Variations for Panuveitis

Expression for Panuveitis

Search GEO for disease gene expression data for Panuveitis.

Pathways for Panuveitis

Pathways related to Panuveitis according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 CD40LG HLA-B HLA-DQB1 HLA-DRB1 IL10 IL17A
2
Show member pathways
12.6 HLA-B HLA-DQB1 HLA-DRB1 TNF
3
Show member pathways
12.48 HLA-B IL10 IL17A TNF
4 12.32 CD40LG IL10 IL17A TNF TNFRSF1B
5
Show member pathways
12.31 CD40LG TNF TNFRSF1B
6
Show member pathways
12.28 CD40LG IL10 IL17A TNF
7 12.27 HLA-B HLA-DQB1 HLA-DRB1 TNF
8
Show member pathways
12.14 HLA-DQB1 HLA-DRB1 IL10 IL17A TNF
9 12.13 HLA-B HLA-DQB1 HLA-DRB1 IL10
10 12.03 HLA-DQB1 HLA-DRB1 IL10 TNF
11
Show member pathways
11.97 CD40LG HLA-B HLA-DQB1 HLA-DRB1 IL10 IL17A
12 11.96 HLA-B HLA-DQB1 HLA-DRB1
13 11.92 CD40LG HLA-B HLA-DQB1 HLA-DRB1
14 11.75 HLA-DQB1 HLA-DRB1 TNF
15 11.73 IL10 IL17A TNF TNFRSF1B
16 11.66 IL10 IL17A TNF
17
Show member pathways
11.63 CD40LG HLA-DQB1 HLA-DRB1 IL10 TNF
18
Show member pathways
11.59 CD40LG TNF TNFRSF1B
19 11.51 HLA-DQB1 HLA-DRB1 IL17A TNF
20 11.46 HLA-DQB1 HLA-DRB1 IL10
21 11.38 IL10 TNF TNFRSF1B
22 11.36 CD40LG IL10 TNF
23 11.09 HLA-DRB1 IL10 TNF

GO Terms for Panuveitis

Cellular components related to Panuveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.87 CD40LG IL10 IL17A RBP3 TNF TNFRSF1B
2 external side of plasma membrane GO:0009897 9.46 CD40LG HLA-DRB1 IL17A TNF
3 MHC class II protein complex GO:0042613 9.26 HLA-DQB1 HLA-DRB1
4 ER to Golgi transport vesicle membrane GO:0012507 9.13 HLA-B HLA-DQB1 HLA-DRB1
5 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.8 HLA-B HLA-DQB1 HLA-DRB1

Biological processes related to Panuveitis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.9 CD40LG IL10 IL17A TNF
2 cytokine-mediated signaling pathway GO:0019221 9.83 IL10 IL17A TNF TNFRSF1B
3 cellular response to lipopolysaccharide GO:0071222 9.76 IL10 TNF TNFRSF1B
4 tumor necrosis factor-mediated signaling pathway GO:0033209 9.75 CD40LG TNF TNFRSF1B
5 apoptotic signaling pathway GO:0097190 9.69 TNF TNFRSF1B UACA
6 T cell costimulation GO:0031295 9.65 CD40LG HLA-DQB1 HLA-DRB1
7 inflammatory response GO:0006954 9.65 CD40LG IL10 IL17A TNF TNFRSF1B
8 interferon-gamma-mediated signaling pathway GO:0060333 9.63 HLA-B HLA-DQB1 HLA-DRB1
9 negative regulation of interleukin-6 production GO:0032715 9.61 IL10 TNF
10 negative regulation of interferon-gamma production GO:0032689 9.61 HLA-DRB1 IL10
11 positive regulation of osteoclast differentiation GO:0045672 9.59 IL17A TNF
12 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.57 TNF TNFRSF1B
13 negative regulation of growth of symbiont in host GO:0044130 9.56 IL10 TNF
14 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.55 HLA-DQB1 HLA-DRB1
15 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.54 IL10 TNF
16 antigen processing and presentation GO:0019882 9.5 HLA-B HLA-DQB1 HLA-DRB1
17 endothelial cell apoptotic process GO:0072577 9.49 IL10 TNF
18 negative regulation of cytokine secretion involved in immune response GO:0002740 9.43 IL10 TNF
19 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.4 HLA-DQB1 HLA-DRB1
20 regulation of immunoglobulin secretion GO:0051023 9.37 CD40LG TNF
21 immune response GO:0006955 9.28 CD40LG CYP11B1 HLA-B HLA-DQB1 HLA-DRB1 IL10
22 receptor biosynthetic process GO:0032800 9.16 IL10 TNF
23 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 8.96 HLA-DQB1 HLA-DRB1

Molecular functions related to Panuveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 CD40LG IL10 IL17A TNF
2 MHC class II receptor activity GO:0032395 9.16 HLA-DQB1 HLA-DRB1
3 peptide antigen binding GO:0042605 8.8 HLA-B HLA-DQB1 HLA-DRB1

Sources for Panuveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....